ClinicalTrials.gg
RecruitingNCT07535112Updated Oct 5, 2026

A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D Mutation

A Phase 1 interventional study of BAY 3771249 and Cetuximab in Advanced/Metastatic Colorectal Adenocarcinoma, sponsored by Bayer. Recruiting at 21 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Bayer · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Oct 5, 2026Site recruiting status changedEligibility revised+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
130
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Researchers are looking for a better way to treat people who have advanced or metastatic colorectal cancer (CRC) with a specific mutation, the G12D mutation, in a protein called KRAS.

Colorectal cancer (CRC) is a common type of cancer that affects the large bowel (colon) or the rectum (the section at the end of the bowel). When CRC spreads to other parts of the body, it is called advanced or metastatic CRC. Some people with CRC have the G12D mutation in the KRAS protein. This mutation is linked to a poorer outlook and fewer treatment options. Currently, there are no approved treatments that specifically target this mutation.

KRAS is a protein that helps control how cells grow and divide. When it is mutated, it can cause cells to grow uncontrollably, leading to cancer. The study drug, BAY 3771249, is designed to block the activity of KRAS with G12D mutation, which may help slow or stop the growth of cancer cells. BAY 3771249 can be given alone or together with another drug called cetuximab.

The main purpose of this study is to learn how safe BAY 3771249 is, how well people tolerate it, how the body processes the drug, and whether it can help shrink or control tumors in people with advanced or metastatic CRC that has the KRAS G12D mutation. The study will also look at how BAY 3771249 works when given alone or with cetuximab, especially in people who have already tried other treatments for their cancer.

Researchers will measure, among others:

The number and seriousness of health problems (adverse events) after receiving BAY 3771249.

The number of participants who experience a dose-limiting side effect (DLT) at each dose level.

The number of participants whose tumors shrink or disappear (overall response rate, ORR) as measured by standard criteria.

How much of the drug is in the blood over time (AUC) and the highest amount in the blood (Cmax).

Some participants will receive BAY 3771249 alone (monotherapy), and others will receive BAY 3771249 with cetuximab (combination therapy).

The study will start with lower doses and gradually increase to find the highest safe dose (dosage escalation). After the safe dose is found, more participants may join the study to receive it (dosage expansion). In some parts of the study, participants may be randomly assigned to different groups or doses. The study is open-label, meaning both participants and doctors know which treatment is being given.

An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, even if they do not think it is related to the study treatment.

The study doctors and their team will contact participants to learn about their health until they complete the study.

If a participant benefits from the treatment, it might be possible to continue receiving BAY 3771249 after the end of the study. The findings from this study may help develop a new treatment option for people with advanced or metastatic CRC with a KRAS G12D mutation.

02

Conditions studied

  • Advanced/Metastatic Colorectal Adenocarcinoma
03

In context

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 5, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • KRAS G12D mutated solid tumor
  • Participant must be ≥18 years old or the legal age of consent in the jurisdiction in which the study is taking place when signing the screening ICF
  • At least one as per v1.1. outside the CNS
  • performance status (ECOG PS) of ≤1
  • Male or Female: use by participant or participant's partners should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • of at least 3 months in the opinion of the Investigator
  • Histologically/ documented diagnosis of advanced/ adenocarcinoma of the colon and rectum.
  • Adequate hematologic and end-organ function

Exclusion criteria

Exclusion Criteria:

  • or carcinomatous meningiti
  • Uncontrolled and/or active/symptomatic .
  • Significant traumatic injury or major surgical procedure within 4 weeks of first dose of study intervention
  • Known to any component of study intervention
  • Previous (within 3 years) or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in the respective substudy.
  • Active infection requiring systemic anti-infective therapy within 14 days of first dose of study intervention
  • Known infection
  • Active virus (HBV) infection
  • Active virus (HCV) infection
  • Significant cardiac disorder
  • History of risk factors for torsade de pointes (TdP) (e.g., heart failure, family history of long syndrome)
  • Participants with inadequately managed diabetes as assessed by the Investigator
  • Toxicities from prior anticancer therapy, defined as not having resolved to Grade ≤1 or as specified in the respective substudy protocol as per v.6.0 with the following exceptions: Alopecia of any grade, Peripheral neuropathy Grade ≤2, endocrine disorders Grade ≤2 managed with stable endocrine replacement therapy
  • History of (non-infectious) pneumonitis/interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis (unless it has resolved without sequelae without use of ), or any evidence of clinically-active pneumonitis/ILD
  • History of the following eye disorders: keratitis, ulcerative keratitis
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
130 participants (estimated)

Study arms

  • Experimental
    Dosage escalation

    In the dosage escalation part, different dose levels of BAY 3771249 administered as monotherapy and in combination with cetuximab are planned.

    Drug: BAY 3771249 · Drug: Cetuximab

  • Experimental
    Dosage expansion

    In the dosage expansion part, participants will receive BAY 3771249 either as monotherapy or in combination with cetuximab until disease progression as defined by RECIST v1.1, the occurrence of unacceptable toxicity, or the fulfillment of any other withdrawal criteria.

    Drug: BAY 3771249 · Drug: Cetuximab

Interventions

  • DrugBAY 3771249

    Oral

  • Intravenous (IV) infusion

06

What researchers measure

Primary outcomes

  1. Change from baseline in laboratory test results

    Hematology, serum chemistry, urinalysis and coagulation tests. Applicable in Dosage escalation and expansion

    Time frame: Up to approximately 2 years

  2. Change from baseline in vital signs: Blood pressure

    Applicable in Dosage escalation and expansion

    Time frame: Up to approximately 2 years

  3. Change from baseline in vital signs: Body temperature

    Applicable in Dosage escalation and expansion

    Time frame: Up to approximately 2 years

  4. Change from baseline in vital signs: Oxygen saturation

    Applicable in Dosage escalation and expansion

    Time frame: Up to approximately 2 years

  5. Change from baseline in vital signs: Pulse rate

    Applicable in Dosage escalation and expansion

    Time frame: Up to approximately 2 years

  6. Change from baseline in vital signs: Respiratory rate

    Applicable in Dosage escalation and expansion

    Time frame: Up to approximately 2 years

  7. Number of participants experiencing a dose-limiting toxicity (DLT) at each dosage

    Applicable in Dose escalation part

    Time frame: Up to approximately 3 weeks

  8. Number of participants with Treatment-emergent adverse events (TEAEs)

    Applicable in Dosage escalation and expansion

    Time frame: Up to approximately 2 years.

  9. Objective response rate (ORR) as determined by the Investigator according to RECIST v1.1

    Applicable in Dosage escalation and expansion

    Time frame: Up to approximately 2 years

  10. Severity of TEAEs

    Applicable in Dosage escalation and expansion

    Time frame: Up to approximately 2 years.

Secondary outcomes

  1. Pharmacokinetics (PK) parameters such as area under the concentration vs time curve (AUC)

    Applicable in Dosage escalation

    Time frame: Up to approximately 2 years

  2. PK parameters such as maximum observed drug concentration (Cmax)

    Applicable in Dosage escalation

    Time frame: Up to approximately 2 years

07

Study locations

6 of 21 sites recruiting
  • Mayo Clinic - Cancer Center - Phoenix
    Phoenix, Arizona 85054, United States
    Not yet recruiting
  • City of Hope - Duarte Cancer Center
    Duarte, California 91010, United States
    Recruiting
  • UC San Diego Health - Moores Cancer Center
    San Diego, California 92037, United States
    Not yet recruiting
  • Sarah Cannon Research Institute at HCA HealthONE Presbyterian St. Luke's
    Denver, Colorado 80218, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Icahn School of Medicine at Mount Sinai - Oncology
    New York, New York 10029, United States
    Not yet recruiting
  • NEXT Dallas - Oncology Department
    Irving, Texas 75039, United States
    Recruiting
  • START | San Antonio
    San Antonio, Texas 78229, United States
    Recruiting
  • Border Medical oncology - Albury Wodonga Regional Cancer Centre
    Albury, New South Wales 2640, Australia
    Not yet recruiting
  • Calvary Mater Hospital Newcastle - Oncology
    Waratah, New South Wales 2298, Australia
    Recruiting
  • Cabrini Health Oncology Research
    Malvern, Victoria 3144, Australia
    Not yet recruiting
  • Ghent University Hospital | Drug Research Unit Department
    Ghent, East Flanders 9000, Belgium
    Not yet recruiting
  • Rigshospitalet Copenhagen University Hospital | Oncology Department
    Copenhagen, Capital Region / Region Hovedstaden 2100, Denmark
    Not yet recruiting
  • Odense University Hospital | Svendborg Sygehus - Oncology Department
    Odense, Region of Southern Denmark / Region Syddanmark 5000, Denmark
    Not yet recruiting
  • HUS-Yhtymä, Helsingin yliopistollinen sairaala (HUS) - Syöpäkeskus
    Helsinki, Uusimaa 00029, Finland
    Not yet recruiting
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Fase I
    Roma, 00128, Italy
    Not yet recruiting
  • Nederlands Kanker Instituut
    Amsterdam, North Holland 1066 CX, Netherlands
    Not yet recruiting
  • National University Hospital Medical Centre
    Singapore, 119074, Singapore
    Recruiting
  • National Cancer Center Singapore - Oncology Department
    Singapore, 168583, Singapore
    Recruiting
  • Hospital Universitari Vall D Hebron | Oncologia
    Barcelona, Barcelona 08035, Spain
    Not yet recruiting
  • Hospital Universitario Hm Sanchinarro | Oncologia
    Madrid, Madrid 28050, Spain
    Not yet recruiting
  • Karolinska Universitetssjukhuset - Solna - Fas I-enheten Solna CKC
    Stockholm, Stockholm County 171 76, Sweden
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: No — Currently, there is no established plan for the sharing of Individual Patient Data (IPD) from this study. The availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA 'Principles for responsible clinical trial data sharing.' This pertains to the scope, timepoint, and process of data access. As such, Bayer commits to considering requests from qualified researchers for patient- / study-level clinical trial data, and documents from clinical trials involving medicines and indications approved in the US and EU. However, this commitment does not reflect an active IPD sharing plan. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Researchers can use www.vivli.org to request access to IPD and documents from clinical studies to conduct research. Information on Bayer's criteria for listing studies is provided in the member section of the portal.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Jul 2029, 39 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2026
First posted
Apr 16, 2026
StartActual
Apr 7, 2026
Primary completionEst.
Jul 27, 2029
CompletionEst.
Jul 9, 2030
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
6 sites added, 6 sites removed. 4 sites changed recruiting status (3 now recruiting, 1 now withdrawn)
Show 4 sites
  • City of Hope - Duarte Cancer Center · Duarte, United StatesNot yet recruiting→Recruiting
  • Sarah Cannon Research Institute at HCA HealthONE Presbyterian St. Luke's · Denver, United StatesNot yet recruiting→Withdrawn
  • Unnamed siteNot yet recruiting→Recruiting
  • National University Hospital Medical Centre · Singapore, SingaporeNot yet recruiting→Recruiting
Show 6 added (2 Denmark, 2 Spain, 1 Belgium, 1 Sweden)
  • Ghent University Hospital | Drug Research Unit Department · Ghent, Belgium
  • Rigshospitalet Copenhagen University Hospital | Oncology Department · Copenhagen, Denmark
  • Odense University Hospital | Svendborg Sygehus - Oncology Department · Odense, Denmark
  • Hospital Universitari Vall D Hebron | Oncologia · Barcelona, Spain
  • Hospital Universitario Hm Sanchinarro | Oncologia · Madrid, Spain
  • Karolinska Universitetssjukhuset - Solna - Fas I-enheten Solna CKC · Stockholm, Sweden
Show 6 removed
  • Ghent University Hospital | Drug Research Unit Department · Ghent, Belgium
  • Rigshospitalet - Kræftbehandling · Copenhagen, Denmark
  • Odense University Hospital - Oncology Department · Odense, Denmark
  • Hospital Universitari Vall D Hebron | Oncologia · Barcelona, Spain
  • Hospital Universitario Hm Sanchinarro | Oncologia · Madrid, Spain
  • Karolinska Universitetssjukhuset - Fas I-enheten Solna CKC · Stockholm, Sweden
Oct 5, 2026
Eligibility
1 exclusion criterion edited
What changed in the criteria
Exclusion criteria
  • EditedLeptomeningeal disease or carcinomatous meningitismeningiti
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    6 sites added, 6 sites removed. 4 sites changed recruiting status (3 now recruiting, 1 now withdrawn)
    Show 4 sites
    • City of Hope - Duarte Cancer Center · Duarte, United StatesNot yet recruiting→Recruiting
    • Sarah Cannon Research Institute at HCA HealthONE Presbyterian St. Luke's · Denver, United StatesNot yet recruiting→Withdrawn
    • Unnamed siteNot yet recruiting→Recruiting
    • National University Hospital Medical Centre · Singapore, SingaporeNot yet recruiting→Recruiting
    Show 6 added (2 Denmark, 2 Spain, 1 Belgium, 1 Sweden)
    • Ghent University Hospital | Drug Research Unit Department · Ghent, Belgium
    • Rigshospitalet Copenhagen University Hospital | Oncology Department · Copenhagen, Denmark
    • Odense University Hospital | Svendborg Sygehus - Oncology Department · Odense, Denmark
    • Hospital Universitari Vall D Hebron | Oncologia · Barcelona, Spain
    • Hospital Universitario Hm Sanchinarro | Oncologia · Madrid, Spain
    • Karolinska Universitetssjukhuset - Solna - Fas I-enheten Solna CKC · Stockholm, Sweden
    Show 6 removed
    • Ghent University Hospital | Drug Research Unit Department · Ghent, Belgium
    • Rigshospitalet - Kræftbehandling · Copenhagen, Denmark
    • Odense University Hospital - Oncology Department · Odense, Denmark
    • Hospital Universitari Vall D Hebron | Oncologia · Barcelona, Spain
    • Hospital Universitario Hm Sanchinarro | Oncologia · Madrid, Spain
    • Karolinska Universitetssjukhuset - Fas I-enheten Solna CKC · Stockholm, Sweden
    Eligibility 1 exclusion criterion edited
    What changed in the criteria
    Exclusion criteria
    • EditedLeptomeningeal disease or carcinomatous meningitismeningiti
    + 3 other changes: identifiers, verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07535112
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Apr 16, 2026
Start date
Apr 7, 2026
Primary completion
Jul 27, 2029 (estimated)
Completion
Jul 9, 2030 (estimated)
Last update
Oct 5, 2026

Study contacts

Bayer Clinical Trials Contact
Contact
clinical-trials-contact@bayer.com
18888422937

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion